Dr. Oz takes on those bogus for-profit stem cell clinics–and cuts them to shreds – Chicago Tribune
Chicago Tribune |
Dr. Oz takes on those bogus for-profit stem cell clinics–and cuts them to shreds
Chicago Tribune We reported that in a survey of “stem cell tourism,” stem cell scientist Paul Knoepfler of UC Davis and bioethicist Leigh Turner of the University of Minnesota identified 570 clinics around the U.S. offering stem cell “interventions.” Scores were … |
|
Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026: Over 140 Organizations with 8 Approved Gene …
Yahoo Finance The “Viral Vectors and Plasmid DNA Manufacturing Market, 2016-2026” report provides an extensive study of the rapidly growing market of gene therapy vectors, with a special focus on lentivirus, AAV, adenovirus, retrovirus and plasmid DNA. Gene … |
Eurogamer.net |
The copyright row that poleaxed the Elite Dangerous pen-and-paper RPG
Eurogamer.net “It’s in a sort of suspended animation, which stops the clock. We had four days to go. If and when this is resolved and we’re back up and running again, they’ll just start the clock again and we’ll have four days to go. “But some backers have … |
Eurogamer.net |
The copyright row that poleaxed the Elite Dangerous pen-and-paper RPG
Eurogamer.net “It’s in a sort of suspended animation, which stops the clock. We had four days to go. If and when this is resolved and we’re back up and running again, they’ll just start the clock again and we’ll have four days to go. “But some backers have … |
|
CRISPR THERAPTC (CRSP) Given Average Recommendation of “Strong Buy” by Brokerages
The Cerbat Gem CRISPR THERAPTC logo Shares of CRISPR THERAPTC (NASDAQ:CRSP) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts … |
|
Minerva Biotechnologies Launches AlphaSTEM™, A Naïve Stem Cell Culture System
Yahoo Finance “Our products will advance stem cell based disease research as well as accelerate the timeline to clinical applications of regenerative medicine,” said Dr. Cynthia Bamdad, CEO of Minerva Biotechnologies. “Minerva’s stem cell technology solves the … |